Stephen Bloom Showed GLP-1 Curbs Appetite in 1996. Now $1.5 Billion Rides on His Molecule

Share

In January 1996, a team at London’s Hammersmith Hospital reported something odd about a gut hormone. When they injected glucagon-like peptide-1 into the brains of fasted rats, the animals stopped eating. The senior author on that Nature paper was Stephen Bloom, an endocrinologist who had already spent a quarter of a century chasing the chemical messages the gut sends to the rest of the body. Thirty years later, a molecule he invented sits at the center of Pfizer’s obesity strategy, and Blackstone Life Sciences has agreed to provide up to $1.5 billion toward its development.

Stephen Bloom is not a household name, but his career traces almost the entire arc of the idea that hunger can be treated with hormones.

A Gift of Secretin and a Career in the Gut

According to an Imperial College London profile, Bloom’s path into gut hormones began in the late 1960s, when the Swedish endocrinologist Viktor Mutt gave him some secretin to work on. Secretin was the first hormone ever described, and Mutt was a leading specialist in isolating gut peptides. Bloom’s group went on to study the gut’s hormonal signals for decades, first at the Royal Postgraduate Medical School in London, which merged into Imperial in 1997.

For much of that time, appetite was not the main event. Gut hormones were studied for digestion, insulin and blood sugar. Bloom later recalled that food intake was only one of several physiological effects his researchers wanted to investigate.

His group was among the first to show that GLP-1 amplifies insulin release in response to carbohydrates, the property that would later make it a diabetes drug target. But the bigger surprise came from the brain.

The 1996 Rat Experiment That Pointed at Appetite

The 1996 Nature paper, led by first author M.D. Turton with Bloom as senior author, made a simple but consequential claim. The team had found GLP-1 and its receptors in the hypothalamus, a brain region involved in appetite regulation. When they injected GLP-1 directly into the brains of fasted rats, feeding was powerfully inhibited. When they blocked the GLP-1 receptor with a compound called exendin (9-39), already well-fed rats more than doubled their food intake.

The authors concluded that central GLP-1 looked like a physiological signal of fullness. This was an animal study, in rats, with injections into the brain’s ventricles. It did not show that a GLP-1 drug would make people lose weight.

Other groups, including researchers in Denmark and North America, were building the biology of GLP-1 in parallel. Credit for the GLP-1 story is spread across many laboratories, as the long fight over Svetlana Mojsov’s recognition showed. But the Hammersmith paper put appetite firmly on the map at a time when GLP-1 was mainly seen as a blood sugar hormone.

Illustrative reconstruction of laboratory rodent research. Bloom’s team reported that GLP-1 administration into the brains of rats suppressed feeding in 1996. This image does not document the actual experiment.

From Oxyntomodulin to a Spinout Habit

Bloom’s lab did not stop at GLP-1. It turned to oxyntomodulin, a lesser-known sibling from the same proglucagon family. In a 2005 randomized, double-blind trial published in Diabetes, overweight and obese volunteers injected oxyntomodulin under the skin three times a day before meals for four weeks.

They lost an average of 2.3 kilograms, compared with 0.5 kilograms on saline, and ate about a quarter less at the first study meal. It was a small, short human study, but it showed that a second gut hormone could move body weight in people.

Illustrative clinical research scene. In Bloom’s 2005 oxyntomodulin trial, investigators measured food intake and body-weight changes during four weeks of treatment. The people shown are not identified study participants.

The oxyntomodulin work became the basis of Thiakis, a spinout founded in 2005 and sold to Wyeth in 2008, according to Imperial. Bloom’s group also explored combinations. With Professor Tricia Tan, he helped investigate how combinations of gut hormones could influence appetite, weight and blood sugar.

The researchers studied combinations involving GLP-1, oxyntomodulin and peptide YY, as well as GLP-1 with glucagon. The latter pairing brought together appetite suppression and increased energy expenditure. That idea, hitting several hormone pathways at once, is now central to the next wave of obesity drugs.

The transition from one hormone to several was not just a laboratory curiosity. It helped establish the logic behind multi-receptor obesity treatments.

Natural GLP-1 breaks down within minutes. Bloom’s group therefore tackled a different problem: engineering a version that could last around a week. Zihipp was founded in 2019 to develop diabetes and obesity treatments, and in 2023 it was acquired by Metsera, a New York startup launched by Population Health Partners and ARCH Venture Partners.

When Metsera emerged from stealth with $290 million in funding in 2024, Fierce Biotech reported that the Zihipp deal brought a library of more than 20,000 gut hormone peptides and that Bloom had joined Metsera’s research leadership.

How His Molecule Became Pfizer’s Lead Obesity Bet

Pfizer completed its acquisition of Metsera in November 2025 after a bidding war with Novo Nordisk, in a transaction valued at up to roughly $10 billion including contingent payments. Imperial’s announcement of the closing said Bloom had invented the Zihipp candidate that became MET-097i, later renamed PF’3944. Pfizer now calls PF-3944 berobenatide.

In June 2026, Pfizer presented Phase 2b data at the American Diabetes Association’s Scientific Sessions and outlined ten ongoing or planned Phase 3 studies, including research on monthly dosing, knee osteoarthritis and obstructive sleep apnea.

In an exploratory extension of the VESPER-1 study, participants who escalated to a 2.4 mg weekly dose lost an average of 15.9% of body weight after 32 weeks of treatment. Pfizer specifically described that figure as non-placebo-adjusted. It was an encouraging development signal, not a head-to-head demonstration of superiority over existing obesity drugs.

On November 11, Pfizer and Blackstone Life Sciences announced an agreement under which Blackstone-managed funds would cover up to $1.5 billion in development costs for berobenatide through 2028. In exchange, Blackstone would become eligible for milestone-based payments tied to US approval of monthly berobenatide and specified commercial sales milestones.

The financing terms matter. Blackstone has not bought berobenatide, and Pfizer retains ownership and operational control. The deal spreads the expense and risk of late-stage development rather than removing either.

Thirty years after a rat experiment suggested GLP-1 could influence hunger, a drug candidate descended from Bloom’s research is attracting billion-dollar development financing.

Berobenatide is not Pfizer’s only obesity move. The company has also pursued other treatments and markets, including ecnoglutide in China.

What the Record Does Not Yet Show

None of this guarantees that berobenatide will reach patients. Phase 2b results, especially non-placebo-adjusted extension numbers, are not Phase 3 proof. The monthly dosing that distinguishes the drug commercially must still establish its effectiveness, safety and practicality against weekly incumbents from Eli Lilly and Novo Nordisk.

The Blackstone agreement is itself an acknowledgment of development risk. It provides Pfizer with financial flexibility while leaving the drug’s clinical and regulatory outcome unresolved. The size of the potential milestone payments was not disclosed, so the eventual cost of that financing cannot yet be fully assessed.

There are historical limits too. GLP-1’s discovery involved many scientists. Bloom’s 1996 paper was rodent work that built on other researchers’ identification and characterization of the active hormone. It should not be confused with the invention of every GLP-1 medicine now sold.

What stands out is persistence across five decades, from appetite in rats to oxyntomodulin in people to university spinouts that larger pharmaceutical companies acquired.

Imperial says Bloom continues to lead research and supervise doctoral students. His group is also exploring combinations of peptide hormones that could reproduce some of the metabolic effects of bariatric surgery without an operation.

Why Stephen Bloom’s Story Matters Now

The obesity drug market is often told as a contest between the Danish company Novo Nordisk and the American company Eli Lilly. Bloom’s career is a reminder that much of the underlying science came from academic laboratories, and that some of the most valuable molecules now in late-stage trials started as university spinouts.

There is also a longer scientific lesson. Gut hormones were once studied primarily for digestion and blood sugar. Their effects on appetite helped reshape obesity research, and their engineering into longer-lasting medicines opened a route from physiological discovery to commercially viable treatment.

A commitment of up to $1.5 billion to develop a GLP-1 drug is ultimately a bet on research that began with a borrowed hormone sample and a question few people thought was about hunger.

Sources

  1. Nature — Turton MD et al. A role for glucagon-like peptide-1 in the central regulation of feeding, January 4, 1996.
  2. Diabetes — Wynne K et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects, August 2005.
  3. Imperial College London — The discovery that launched a new wave of weight loss drugs, 2025.
  4. Imperial College London — Pfizer wraps up $10bn deal for Imperial obesity drug candidates, November 16, 2025.
  5. Fierce Biotech — With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments, April 2024.
  6. Pfizer — Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Berobenatide, June 6, 2026.
  7. Pfizer — Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program, November 11, 2026.
  8. BioSpace — Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset, November 12, 2026.

Read more

Local News